03.12.2019 Issue 442

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Drugmakers Plan for Post-Gottlieb Landscape

Saturday, March 9th

Drugmakers are preparing for life after Food and Drug Administration (FDA) Commissioner Scott Gottlieb who announced his resignation, effective in about a month, this week.

Analysis: ASP Responsible for Big Savings for Medicare, Seniors

Embattled Pharma Bolsters Lobbying Efforts Amid Pushback

Centene, RxAdvance Look to Shake Up Environment Despite Skepticism

‘The Inventor’ Takes Deep Dive Into Holmes’ Legacy

Xtalks Highlights Webinar by HealthEconomics.Com, Scientist.Com and RTI Health Solutions

Upcoming ISPOR Webinar to Spotlight Top 10 HEOR Trends

Amazon-Berkshire-JPMorgan Venture Unveils Name, Website

FDA Commissioner Gottlieb Resigning

Chernew Says IPI Could Lower Drug Prices, Carry Unintended Consequences

 


Director, Real World Value and Evidence, Oncology

Research Consultant: Outcomes Research

Senior Systematic Reviewer

Senior Principal, Pricing Market Access

Industry Spotlight


Conferences Webinars
Statistical Methods in Economic Evaluation for Health Technology Assessment
    March 18-19, York, UK

Patient Partnering in Clinical Development
    March 19-20, Berlin, Germany

Pharma Pricing and Market Access Congress 2019
    March 19-20, Amsterdam, Netherlands

Indication-Based Pricing Masterclass: Delivering the Win-Win
    March 20, London, UK

Life Sciences Accounting and Reporting Congress
    March 20-22, Philadelphia, Pennsylvania

Designing Benefits and Payment Models for Innovative High-Investment Medications - Proceedings from the AMCP Partnership Forum
    March 12

What Do Value Assessments Miss? Rethinking Value Using New Health Economics Evidence
    March 13

Future Proofing for the 2020s: Market Access Trends
    March 14

On the Rise: Out-of-Pocket Healthcare Spending
    March 20


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Review of Influence: The Institute for Clinical and Economic Review

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
             Truven    
              Evidera    HealthCore    University of FL
Xcenda    OM1    Parexel    Jefferson     Dymaxium
Precision Xtract    Pharmerit    eMax Health    Sciformix
Evidence Partners     ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn